021-51111890
购物车（）
sales@molnova.cn
Ruxolitinib S enantiomer
CAS No. 941685-37-6
Ruxolitinib S enantiomer ( S-Ruxolitinib | INCB-018424 S enantiomer )
产品货号. M16735 CAS No. 941685-37-6
Ruxolitinib (INCB-018424) 的手性是一种有效的、选择性的、口服活性的 JAK1/JAK2 抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥470 | 有现货 |
|
| 10MG | ￥551 | 有现货 |
|
| 50MG | ￥948 | 有现货 |
|
| 100MG | ￥1272 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Ruxolitinib S enantiomer
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Ruxolitinib (INCB-018424) 的手性是一种有效的、选择性的、口服活性的 JAK1/JAK2 抑制剂。
-
产品描述The chirality of Ruxolitinib (INCB-018424), which is a potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively.
-
体外实验RT-PCR Cell Line:Human small airway epithelial cells (SAECs) Concentration:10?μM Incubation Time:12 hours Result:Suppressed IFNβ-induced expression of ISG, IFIT, and IFITM.
-
体内实验Animal Model:Female wild-type C57BL/6J or Nes-gfp27 mice with myeloproliferative neoplasms (MPNs) in peripheral blood Dosage:30 mg/kg (in 0.5% hydroxypropyl methylcellulose after solubilisation in DMSO) Administration: Oral gavage; twice per day separated 10-12 h for 8 weeks Result:Reduced haematopoietic cell expansion in MPN but it did not rescue bone marrow (BM) mesenchymal stem cells (MSCs).
-
同义词S-Ruxolitinib | INCB-018424 S enantiomer
-
通路Angiogenesis
-
靶点JAK
-
受体Chk2|JAK1|JAK2|JAK3|Tyk2
-
研究领域Inflammation/Immunology
-
适应症——
化学信息
-
CAS Number941685-37-6
-
分子量306.365
-
分子式C17H18N6
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESN#CC[C@@H](C1CCCC1)N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2
-
化学全称1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βS)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Quintás-Cardama A, et al. Blood. 2010 Apr 15;115(15):3109-17.
2. Fridman JS, et al. J Immunol. 2010 May 1;184(9):5298-307.
3. Verstovsek S, et al. N Engl J Med. 2010 Sep 16;363(12):1117-27.
